Molina Healthcare, Inc. MOH
Composite 40/100; the shares have moved about 45% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Quality ranks 14/100 — a strong mark against it.
Balance-sheet strength ranks 65/100 — a moderate point in its favour. Momentum ranks 54/100 — a slight point in its favour.
Quality ranks 14/100 — a strong mark against it. Growth ranks 19/100 — a strong mark against it. Valuation ranks 50/100 — a slight mark against it.
What the company does Molina Healthcare provides managed healthcare services to low-income families and individuals under Medicaid, Medicare, and state insurance marketplaces. Its four segments—Medicaid, Medicare, Marketplace, and Other—serve vulnerable populations across the U.S.
Key financials Molina’s profitability metrics are weak: ROE -0.2%, ROA 1.2%, and net margins -0.0%. Revenue declined -5.7% and EPS fell -75.3%, while gross margins stand at 8.4%. Debt/equity is 0.95, with interest coverage at 0.97 and a current ratio of 1.68.
Stock health Technical momentum is mixed: 12-month return is 20.88%, but the stock is -20.49% below its 52-week high and RSI(14) is 34.60. The Altman Z-score of 4.06 suggests low bankruptcy risk, but Piotroski F-Score of 6/9 indicates moderate financial health.
Price vs fair value Molina trades at a **PREMIUM of 60.30%** versus our fair-value estimate of 77.39 and a **discount of 7.41%** to the analyst 12-month target of 209.12. - Trading at a premium despite weak profitability (Key financials). - Analyst target implies 7.41% upside (Analyst 12-month target). - Recent momentum divergence: 20.88% over 12 months vs -20.49% from 52-week high (Momentum). - Weak quality score (19.8) contrasts with high valuation metrics (P/E 1234.69).
Looking forward Forward P/E of 37.74 and EV/EBITDA of 14.42 suggest high expectations. Growth (5.6) and income (50.0) scores are low, while valuation (50.3) is neutral. Analysts see potential upside, but fundamentals remain challenged.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.